MARINOL provides multiple benefits through one unique pathway, the endocannabinoid system. It was the first cannabinoid approved by the FDA, is the only one designated as schedule III, and is the only cannabinoid approved for use in both HIV/AIDS and cancer chemotherapy patients.
This section gives health care professionals access to a variety of information about MARINOL, including its mechanism of action, the clinical challenges it addresses, the multiple benefits it provides, the dosing recommended to achieve these benefits, the possible side effects, and much more.
Find out more about this unique agent and its uses in HIV/AIDS and oncology. You can also learn more about patient resources and how to get in contact with a sales representative.
